title: Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
abstract: OBJECTIVE
  This study aimed to determine how aprepitant affects the impact of chemotherapy-induced nausea and vomiting (CINV) on daily activities during highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
  
  
  METHODS
  Patients received aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone) or standard antiemetic therapy alone. Data were analyzed from pooled data of two Phase III randomized, double-blind HEC trials and one MEC trial. Patients completed the Functional Living Index-Emesis questionnaire.
  
  
  RESULTS
  A significantly greater percentage of patients receiving aprepitant reported no or minimal CINV impact on daily life (overall total Functional Living Index-Emesis score >6) compared with those receiving standard therapy alone (HEC: 74.4 vs 63.9%, respectively; p < 0.01; MEC: 73.4 vs 66.3%; p < 0.05). In HEC, favorable responses to aprepitant treatment persisted in nausea (70.2 vs 60.9%) and vomiting domains (84.6 vs 68.7%; both p < 0.01). Similar results were seen in MEC.
  
  
  CONCLUSIONS
  Addition of aprepitant reduced CINV impact on daily life compared with standard antiemetic therapy.
authors.affiliation: School of Nursing, Midwifery & Social Work, University of Manchester, Room 5.310, Jean McFarlane Building, University Place, Oxford Road, Manchester, M13 9PL, UK.
authors.forename: Alex
authors.initials: A
authors.lastname: Molassiotis
authors.forename: Allison Martin
authors.initials: AM
authors.lastname: Nguyen
authors.forename: Cynthia N
authors.initials: CN
authors.lastname: Rittenberg
authors.forename: Alex
authors.initials: A
authors.lastname: Makalinao
authors.forename: Alexandra
authors.initials: A
authors.lastname: Carides
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000077608:Aprepitant; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant